Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice
- Huanxia Jia
- Zhenya Gao
- Fang Yu
- Hongfang Guo
- Baoyu Li
Affiliations: School of Medicine, Xuchang University, Xuchang, Henan 461000, P.R. China, Department of General Surgery, The Secondary Hospital of Tianjin Medical University, Tianjin 300211, P.R. China
- Published online on: March 1, 2021 https://doi.org/10.3892/etm.2021.9885
Copyright: © Jia
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Hepatocellular carcinoma (HCC) is a common type of tumor with high mortality worldwide. Investigations associated with the molecular etiology of HCC and screening novel therapeutic targets are still urgently in need. Anillin (ANLN), as a type of evolutionarily conserved actin‑binding protein, is involved in multiple cellular processes. ANLN widely affected the progression and metastasis of several types of cancer, and its overexpression was frequently demonstrated in previous studies. The present study demonstrated high expression of ANLN in human HCC tissues, which was also associated the prognosis of patients with HCC. The associations between ANLN expression and the clinicopathological features were determined, including the number of tumor nodes (P=0.011) and tumor size (P=0.003) of patients with HCC. It was found that ANLN promoted cell proliferation, invasion and migration of HCC cells in vitro, and affected tumor growth in vivo. Therefore, ANLN is suggested as a promising therapeutic target for the treatment of HCC.